Relay Therapeutics, Inc.
RLAY
$19.86
-$0.07-0.35%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -48.30% | -60.93% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -48.30% | -60.93% | -- | -- | -- |
| Cost of Revenue | 19.70% | -4.40% | -12.56% | -11.39% | -30.54% |
| Gross Profit | -20.43% | -2.17% | 23.42% | 11.39% | 31.28% |
| SG&A Expenses | 7.81% | -41.15% | -33.86% | -36.70% | -32.34% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.61% | -11.84% | -17.71% | -16.58% | -30.86% |
| Operating Income | -18.19% | 7.40% | 25.95% | 16.58% | 31.47% |
| Income Before Tax | -18.94% | 4.90% | 27.78% | 15.84% | 23.68% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -18.94% | 4.90% | 27.78% | 15.84% | 23.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.94% | 4.90% | 27.78% | 15.84% | 23.68% |
| EBIT | -18.19% | 7.40% | 25.95% | 16.58% | 31.47% |
| EBITDA | -19.27% | 6.66% | 25.48% | 16.17% | 31.52% |
| EPS Basic | -0.44% | 10.52% | 30.32% | 31.55% | 40.82% |
| Normalized Basic EPS | -0.43% | 10.51% | 27.40% | 31.55% | 47.31% |
| EPS Diluted | -0.44% | 10.52% | 30.32% | 31.55% | 40.82% |
| Normalized Diluted EPS | -0.43% | 10.51% | 27.40% | 31.55% | 47.31% |
| Average Basic Shares Outstanding | 18.44% | 6.27% | 3.63% | 22.93% | 28.94% |
| Average Diluted Shares Outstanding | 18.44% | 6.27% | 3.63% | 22.93% | 28.94% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |